- Home
- TVGN vs ACCS Comparison
TVGN vs ACCS Comparison
Compare TVGN & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | ACCS |
|---|---|---|
| Founded | 2020 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Publishing |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 17.6M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TVGN | ACCS |
|---|---|---|
| Price | $6.13 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | ★ 7.3K | 6.4K |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 139.36 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $22,619,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.14 | $3.74 |
| 52 Week High | $32.50 | $11.34 |
Technical Indicators
Market Signals| Indicator | TVGN | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 38.45 | 19.25 |
| Support Level | $3.89 | N/A |
| Resistance Level | $7.55 | $4.99 |
| Average True Range (ATR) | 0.50 | 0.20 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 14.07 | 0.88 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.